Prof. Fred Saad (University of Montreal Hospital Centre, Université de Montréal, Quebec, Canada) joins touchONCOLOGY to discuss clinical trial highlights in prostate cancer presented at EMSO 2022. He highlights the results from one of the phase 3 STAMPEDE trials, investigating combination abiraterone and enzalutamide or abiraterone and prednisolone, for metastatic hormone sensitive prostate cancer (mHSPC), […]